Illumina, Inc. (ILMN) Stock

Healthcare · Diagnostics & Research · Member of S&P 500, NASDAQ 100

Illumina, Inc. (ILMN) closed at USD 271.76 on 2026-10-14, a change of +177.9 % over the past year, with a market capitalization of USD 40.46B.

Illumina, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Illumina, Inc. key figures

Previous close

USD 271.76 (2026-10-14)

1-year change

+177.9 %

Market cap

USD 40.46B

Enterprise value

USD 41.82B

P/E ratio (trailing)

49.71

P/E ratio (forward)

43.79

EPS (trailing)

5.39

EPS (forward)

6.12

PEG ratio

3.35

Price to book

14.26

Revenue growth

9.4 %

Earnings growth

-9.4 %

Dividend per share (trailing)

0.00

Short ratio

2.43

Employees

8,600

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Illumina, Inc.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Illumina, Inc. and compare it with other stocks.